Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma-Reference-Cited by-同舟云学术

Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma

Published:2022-10 Issue:10 Volume:3 Page:664-681.e6
ISSN:2666-6340
Container-title:Med
language:en
Short-container-title:Med

Author:

You Rui,Zou Xiong,Ding Xi,Zhang Wei-Jing,Zhang Meng-Xia,Wang Xiao,Xu Han-Shi,Liu Yong-Long,Ouyang Yan-Feng,Duan Chong-Yang,Gu Chen-Mei,Wang Zhi-Qiang,Liu You-Ping,Hua Yi-Jun,Huang Pei Yu,Chen Ming-Yuan

Publisher

Elsevier BV

Subject

General Medicine

Reference69 articles.

1. The prevalence and prevention of nasopharyngeal carcinoma in China;Cao;Chin. J. Cancer,2011

2. Prognostic model for stratification of radioresistant nasopharynx carcinoma to curative salvage radiotherapy;Li;J. Clin. Oncol.,2018

3. Management of locally recurrent nasopharyngeal carcinoma;Lee;Cancer Treat Rev.,2019

4. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial;Zhang;Lancet,2016

5. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials;Fang;Lancet Oncol.,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy;Scientific Reports;2024-01-20

2. Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial;Nature Communications;2023-08-14

3. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study;eClinicalMedicine;2023-07

4. Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors;International Immunopharmacology;2023-02

5. The efficacy and safety of VEGF/VEGFR inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A meta-analysis;Oral Oncology;2022-12